EN
TR
Estrogen in Luteal Phase Support: Effects on IVF-ICSI Antagonist Protocol Pregnancy Results
Abstract
Aim: This study aimed to investigate the effect of luteal phase support (LPS) with estradiol in addition to progesterone on pregnancy outcomes in patients who underwent ovulation induction with GnRH antagonist protocol in in vitro fertilization- intracytoplasmic sperm injection (IVF-ICSI).
Materials and Methods: This retrospective study was carried out at reproductive medicine center of Necmettin Erbakan University Meram Medical Faculty. The study enrolled 128 patients undergoing ICSI on an antagonist protocol for controlled ovarian hyperstimulation. Study group administered 7.8 mg transdermal estradiol (E2) daily in addition to progesterone for LPS (n=64). Control group administered only progesterone for LPS (n=64). All women received 200 mg progesterone 3x1 intravaginal daily and 50 mg progesterone intramuscular injection per two days for LPS. Blood samples were drawn 12 days after embryo transfer for β-hCG. If the result is negative, treatment was discontinued, if positive, estradiol was discontinued and progesterone support was continued until the 10th week of gestation. Pregnancy outcomes were the main endpoint.
Results: There was no difference between groups in terms of biochemical pregnancy, clinical pregnancy, abortus and ongoing pregnancy rates.
Conclusion: In our study, the use of estrogen for luteal phase support in GnRH antagonist protocol did not show any difference on pregnancy outcomes.
Keywords
References
- 1. Ubaldi F, Bourgain C, Tournaye H, Smitz J, Van Steirteghem A, Devroey P. Endometrial evaluation by aspiration biopsy on the day of oocyte retrieval in the embryo transfer cycles in patients with serum progesterone rise during the follicular phase. Fertil Steril 1997;67(3):521-6.
- 2. Pados G, Devroey P. Luteal phase support. Assist Reprod Rev 1992;2:148.
- 3. Fatemi HM, Camus M, Kolibianakis EM et al. The luteal phase of recombinant follicle stimulating hormone/ gonadotropin releasing hormone antagonist in vitro fertilization cycles during supplementation with progesterone or progesterone and estradiol. Fertil Steril 2006;87(3):504-8.
- 4. Chang EM, Han JE, Won HJ, Kim YS, Yoon TK, Lee WS. Effect of estrogen priming through luteal phase and stimulation phase in poor responders in in-vitro fertilization. J Assist Reprod Genet 2012;29(3):225-30.
- 5. Fanchin R, CunhaFilho JS, Schonauer LM, Kadoch IJ, CohenBacri P, Frydman R. Coordination of early antral follicles by luteal estradiol administration provides a basis for alternative controlled ovarian hyperstimulation regimens. Fertil Steril 2003;79(2):316-21.
- 6. Fanchin R, Salomon L, CasteloBranco A, Olivennes F, Frydman N, Frydman R. Luteal estradiol pretreatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Hum Reprod 2003;18(12):2698-703.
- 7. Ireland JJ, Richards JS. Acute effects of estradiol and folliclestimulating hormone on specific binding of human [125I] iodofolliclestimulating hormone to rat ovarian granulosa cells in vivo and in vitro. Endocrinol 1978;102:876–83.
- 8. Hutchinson-Williams K, Lunenfeld B, Diamond M, Lagy G, Boyers S, De Cherney A. Human chorionic gonadotropin, estradiol, and progesterone profiles in conception and non-conception cycles in an in vitro fertilization program. Fertil Steril 1989;52:441-445.
Details
Primary Language
English
Subjects
Health Care Administration
Journal Section
Research Article
Publication Date
November 30, 2022
Submission Date
June 3, 2022
Acceptance Date
July 21, 2022
Published in Issue
Year 2022 Volume: 12 Number: 6
APA
Alan, C., & Görkemli, H. (2022). Estrogen in Luteal Phase Support: Effects on IVF-ICSI Antagonist Protocol Pregnancy Results. Journal of Contemporary Medicine, 12(6), 978-983. https://doi.org/10.16899/jcm.1125489
AMA
1.Alan C, Görkemli H. Estrogen in Luteal Phase Support: Effects on IVF-ICSI Antagonist Protocol Pregnancy Results. J Contemp Med. 2022;12(6):978-983. doi:10.16899/jcm.1125489
Chicago
Alan, Cemre, and Hüseyin Görkemli. 2022. “Estrogen in Luteal Phase Support: Effects on IVF-ICSI Antagonist Protocol Pregnancy Results”. Journal of Contemporary Medicine 12 (6): 978-83. https://doi.org/10.16899/jcm.1125489.
EndNote
Alan C, Görkemli H (November 1, 2022) Estrogen in Luteal Phase Support: Effects on IVF-ICSI Antagonist Protocol Pregnancy Results. Journal of Contemporary Medicine 12 6 978–983.
IEEE
[1]C. Alan and H. Görkemli, “Estrogen in Luteal Phase Support: Effects on IVF-ICSI Antagonist Protocol Pregnancy Results”, J Contemp Med, vol. 12, no. 6, pp. 978–983, Nov. 2022, doi: 10.16899/jcm.1125489.
ISNAD
Alan, Cemre - Görkemli, Hüseyin. “Estrogen in Luteal Phase Support: Effects on IVF-ICSI Antagonist Protocol Pregnancy Results”. Journal of Contemporary Medicine 12/6 (November 1, 2022): 978-983. https://doi.org/10.16899/jcm.1125489.
JAMA
1.Alan C, Görkemli H. Estrogen in Luteal Phase Support: Effects on IVF-ICSI Antagonist Protocol Pregnancy Results. J Contemp Med. 2022;12:978–983.
MLA
Alan, Cemre, and Hüseyin Görkemli. “Estrogen in Luteal Phase Support: Effects on IVF-ICSI Antagonist Protocol Pregnancy Results”. Journal of Contemporary Medicine, vol. 12, no. 6, Nov. 2022, pp. 978-83, doi:10.16899/jcm.1125489.
Vancouver
1.Cemre Alan, Hüseyin Görkemli. Estrogen in Luteal Phase Support: Effects on IVF-ICSI Antagonist Protocol Pregnancy Results. J Contemp Med. 2022 Nov. 1;12(6):978-83. doi:10.16899/jcm.1125489